Latest news
Oslo, Norway, 05 February 2019 – PCI Biotech invites to a presentation of the company’s fourth quarter and preliminary 2018 report on Wednesday 13 February 2019 at Oslo Cancer Cluster Innovation Park. Time: Wednesday February 13, 08:30am – 09:30am CET (local time). Venue: Jónas Einarsson aud. (2nd floor, entrance 2B), Oslo Cancer Cluster Innovation Park, […]
Preliminary confirmation of safety read-out from the fimaChem Phase I extension study in bile duct cancer
Oslo (Norway), 20 December 2018 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announced preliminary confirmation that the safety endpoint has been reached in the Phase I extension study without the report of any adverse reactions which would limit the proposed plan of including up to two fimaCHEM treatments in the pivotal […]
Extension of preclinical research collaboration agreement with a top-10 large pharma company
Oslo (Norway), 18 December 2018 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announced that they are extending the preclinical research collaboration with an undisclosed top-10 pharma company, initiated in September 2015. The extended evaluation period spans over 6 months, until the end of June 2019, and may be further extended. The […]